PharmAla Advances MDXX Manufacturing and Drug Pipeline
Toronto, Ontario, Canada, August 21, 2026 PharmAla Biotech Holdings Inc., a biotechnology company focused on the research, development, and...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Toronto, Ontario, Canada, August 21, 2026 PharmAla Biotech Holdings Inc., a biotechnology company focused on the research, development, and...
TORONTO, Ontario, March 3, 2026 PharmAla Biotech Holdings Inc. has entered a supply and data agreement with Nautilus Sanctuary...
TORONTO, Canada | December 24, 2025 — PharmAla Biotech Holdings has released its audited financial statements for fiscal year-end...
